TW200716632A - Integrase inhibitor compounds - Google Patents

Integrase inhibitor compounds

Info

Publication number
TW200716632A
TW200716632A TW095117351A TW95117351A TW200716632A TW 200716632 A TW200716632 A TW 200716632A TW 095117351 A TW095117351 A TW 095117351A TW 95117351 A TW95117351 A TW 95117351A TW 200716632 A TW200716632 A TW 200716632A
Authority
TW
Taiwan
Prior art keywords
inhibitor compounds
integrase inhibitor
integrase
compounds
hiv
Prior art date
Application number
TW095117351A
Other languages
English (en)
Inventor
Zhenhong R Cai
Rachael A Lansdown
Salman Y Jabri
Samuel E Metobo
Hao-Lun Jin
Michael R Mish
Choung U Kim
Richard M Pastor
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of TW200716632A publication Critical patent/TW200716632A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW095117351A 2005-05-16 2006-05-16 Integrase inhibitor compounds TW200716632A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68169005P 2005-05-16 2005-05-16

Publications (1)

Publication Number Publication Date
TW200716632A true TW200716632A (en) 2007-05-01

Family

ID=37432118

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095117351A TW200716632A (en) 2005-05-16 2006-05-16 Integrase inhibitor compounds

Country Status (5)

Country Link
US (1) US20070072831A1 (zh)
EP (1) EP1888581A2 (zh)
AR (1) AR057023A1 (zh)
TW (1) TW200716632A (zh)
WO (1) WO2006125048A2 (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2007076005A2 (en) * 2005-12-21 2007-07-05 Gilead Sciences, Inc. Processes and intermediates useful for preparing integrase inhibitor compounds
AU2007254190A1 (en) 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
AU2007307635A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
US20090291921A1 (en) * 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
ES2572631T3 (es) 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
WO2010011814A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP5551697B2 (ja) * 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN102245572B (zh) 2008-12-11 2015-03-25 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2770282A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013102936A1 (en) * 2012-01-03 2013-07-11 Council Of Scientific & Industrial Research N-(3-((diethylamino) methyl)-4-hydroxyphenyl)-n-(quinolin-4-yl) sulfonamides for the treatment of tuberculosis and process of preparation thereof
MX2014014109A (es) 2012-05-23 2016-03-31 Savira Pharmaceuticals Gmbh Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
BR112014029016A8 (pt) 2012-05-23 2018-01-09 European Molecular Biology Laboratory derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
KR20150039832A (ko) 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US9199987B2 (en) 2013-01-08 2015-12-01 Savira Pharmaceuticals Gmbh Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease
HK1211287A1 (zh) 2013-01-08 2016-05-20 Savira Pharmaceuticals Gmbh 吡啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途
NO2865735T3 (zh) 2013-07-12 2018-07-21
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (zh) 2014-06-20 2018-06-23
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US11180758B2 (en) 2016-02-24 2021-11-23 The Johns Hopkins University Antiviral proteins and their uses in therapeutic methods
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
EP3494998A1 (en) 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
BR112020011727A2 (pt) 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
EP3494999A1 (en) 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
BR112021012110A2 (pt) 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU3118200A (en) * 1998-12-14 2000-07-03 Merck & Co., Inc. Hiv integrase inhibitors
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
AU8009900A (en) * 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
PL360944A1 (en) * 2000-10-12 2004-09-20 Merck & Co, Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2456155A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
AU2004234087A1 (en) * 2003-04-28 2004-11-11 Tibotec Pharmaceuticals Ltd. HIV integrase inhibitors
WO2005042773A1 (en) * 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005117904A2 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
WO2006122403A1 (en) * 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists

Also Published As

Publication number Publication date
WO2006125048A2 (en) 2006-11-23
AR057023A1 (es) 2007-11-14
WO2006125048A3 (en) 2007-08-09
EP1888581A2 (en) 2008-02-20
US20070072831A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
TW200716632A (en) Integrase inhibitor compounds
WO2007136714A3 (en) Integrase inhibitors
WO2009067541A3 (en) Integrase inhibitors
PL1742642T3 (pl) Analogi fosfonianowe związków inhibitorów integrazy HIV
TW200640924A (en) VEGF-R2 inhibitors and methods
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
TW200734315A (en) Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
NO20071050L (no) Rapamycin-polymorf II og anvendelser derav
NO20052378D0 (no) Pre-organiserte trisykliske integraseinhibitorforbindelser
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
PL1761520T3 (pl) Inhibitory kinazy
WO2012002741A3 (en) Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
TNSN08191A1 (en) Kinase inhibitors
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
TW200624426A (en) BACE inhibitors
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
MY142105A (en) Leukotriene biosynthesis inhibitors
UA85505C2 (en) Kinase inhibitors
TW200732281A (en) Heterocyclic CETP inhibitors
TWI374886B (en) Processes for preparing intermediates of pemetrexed